Baird lowered the firm’s price target on Karyopharm (KPTI) to $54 from $75 and keeps an Outperform rating on the shares. The firm updated its model following its reverse stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm target adjusted to $7 from $56 at H.C. Wainwright
- Karyopharm trading halted, news pending
- Karyopharm implementing 1-for-15 reverse stock split
- Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
- Karyopharm’s Earnings Call: Growth Amid Financial Challenges